CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双特异性抗体在多发性骨髓瘤治疗中的应用
英文原题：Bispecific Antibodies in the Treatment of Multiple Myeloma.
查看英文原题
Bispecific Antibodies in the Treatment of Multiple Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）的治疗正在迅速发展。近年来，基于T细胞的新型免疫疗法成为复发/难治性MM患者的新治疗策略，包括嵌合抗原受体（CAR）修饰T细胞和双特异性抗体（bsAbs）等高效新选择。目前，B细胞成熟抗原是MM中CAR-T 细胞和bsAb疗法最常用的靶抗原。不同临床试验的结果已证明bsAb在RRMM中具有令人鼓舞的疗效和可接受的安全性。
展开英文摘要原文
The treatment of multiple myeloma (MM) is evolving rapidly. In recent years, T-cell-based novel immunotherapies emerged as new treatment strategies for patients with relapsed/refractory MM, including highly effective new options like chimeric antigen receptor (CAR)-modified T cells and bispecific antibodies (bsAbs). Currently, B-cell maturation antigen is the most commonly used target antigen for CAR T-cell and bsAb therapies in MM. Results from different clinical trials have demonstrated promising efficacy and acceptable safety profile of bsAb in RRMM.
论文信息
- 作者
- Zhou X、Xiao X、Kortuem KM、Einsele H
- 第一作者单位
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.Germany
- 通讯作者单位
- Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany. Electronic address: Einsele_H@ukw.de.Germany
- 文献类型
- 综述
- 期刊
- Hematology/oncology clinics of North America2024 Apr
- 原文标识
- PubMed 38199897 · DOI 10.1016/j.hoc.2023.12.003